ATRA Insider Trading

Insider Ownership Percentage: 3.70%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $218,489.87

Atara Biotherapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Atara Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

Atara Biotherapeutics Share Price & Price History

Current Price: $5.53
Price Change: Price Increase of +0.23 (4.34%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for ATRA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$5.53Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for Atara Biotherapeutics (NASDAQ:ATRA)

70.90% of Atara Biotherapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ATRA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$558kbought$976ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M$0$20MTotal InflowsTotal Outflows
Atara Biotherapeutics logo
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Read More on Atara Biotherapeutics

Today's Range

Now: $5.53
Low: $5.16
High: $5.54

50 Day Range

MA: $7.10
Low: $5.30
High: $10.51

52 Week Range

Now: $5.53
Low: $5.01
High: $19.00

Volume

57,867 shs

Average Volume

123,252 shs

Market Capitalization

$32.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Who are the company insiders with the largest holdings of Atara Biotherapeutics?

Atara Biotherapeutics' top insider shareholders include:
  1. Anhco Nguyen (CEO)
  2. Pascal Touchon (CEO)
  3. Eric J Hyllengren (CFO)
  4. Anhco Nguyen (EVP)
  5. Jill Henrich (EVP)
  6. Carol Giltner Gallagher (Director)
  7. Amar Murugan (EVP)
  8. William K Heiden (Director)
Learn More about top insider investors at Atara Biotherapeutics.